Trial
NCT04629339
Study of INCB086550 in Select Solid Tumors
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Incyte Corporation
Collaborators
—
Condition
Non Small Cell Lung Cancer
Intervention
INCB086550
Why stopped
Strategic business decision to terminate the study effective immediately. This is due to a company decision to prioritize another oral PD-L1 inhibitor with a more favorable profile.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-13